PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
26961242-6	2016	We aimed to develop a practical molecular test to aid in distinguishing fibroadenomas from phyllodes tumors in the pre-operative setting.	phyllodes	91-100	activation induced cytidine deaminase	Homo sapiens	50-53
27056456-10	2016	Epithelial expression of ERalpha was significantly higher in fibroadenomas (p<0.001) than in phyllodes tumours.	phyllodes	96-105	estrogen receptor 1	Homo sapiens	25-32
27056456-11	2016	Conversely, both epithelial and stromal expression of ERbeta was significantly higher in phyllodes tumours (p<0.001).	phyllodes	89-98	estrogen receptor 2	Homo sapiens	54-60
27290698-0	2016	Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression.	phyllodes	17-26	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	65-69
27806318-1	2016	Exome sequencing has recently identified highly recurrent MED12 somatic mutations in fibroadenomas (FAs) and phyllodes tumors (PTs).	phyllodes	109-118	mediator complex subunit 12	Homo sapiens	58-63
27806318-3	2016	We show that MED12 mutations are associated with benign behavior of phyllodes tumors, as they are detected less frequently in malignant PTs (27.6%) compared to benign (58.3%) and borderline (63.3%) PTs, respectively (p = 0.0036).	phyllodes	68-77	mediator complex subunit 12	Homo sapiens	13-18
27806318-4	2016	Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors.	phyllodes	0-9	mediator complex subunit 12	Homo sapiens	60-65
27806318-4	2016	Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors.	phyllodes	0-9	mediator complex subunit 12	Homo sapiens	148-153
27806318-4	2016	Phyllodes tumors presented marked temporal heterogeneity of MED12 mutation status, as 50% (3/6) of primary and recurrent phyllodes tumor pairs with MED12 mutation presented different MED12 mutations between the primary and recurrent tumors.	phyllodes	0-9	mediator complex subunit 12	Homo sapiens	148-153
28066593-1	2016	BACKGROUND: A retrospective analysis of diagnoses was performed in patients with phyllodes tumors of the breast (PTB) who received preoperative core needle biopsy (CNB) and had breast surgery at Fudan University Shanghai Cancer Center from January 1, 2002 to April 1, 2013.	phyllodes	81-90	polypyrimidine tract binding protein 1	Homo sapiens	113-116
27628602-9	2016	We conclude from these findings that the hypoglycemic attack was related to the elevated IGF-II level in the giant phyllodes tumor of the breast.	phyllodes	115-124	insulin like growth factor 2	Homo sapiens	89-95
26856273-0	2016	Frequency of MED12 mutations in phyllodes tumors: Inverse correlation with histologic grade.	phyllodes	32-41	mediator complex subunit 12	Homo sapiens	13-18
25652050-1	2015	PURPOSE: To ensure a surgical margin of >=1 cm for the effective treatment of phyllodes tumors of the breast (PTB) a second resection has been recommended, but the outcomes of an extensive series of cases employing the aforementioned criterion cast doubt on this clinical approach.	phyllodes	81-90	polypyrimidine tract binding protein 1	Homo sapiens	113-116
26355235-0	2015	TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.	phyllodes	82-91	telomerase reverse transcriptase	Homo sapiens	0-4
26355235-0	2015	TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast.	phyllodes	82-91	mediator complex subunit 12	Homo sapiens	63-68
26355235-4	2015	RESULTS: Sequencing analyses showed that TERT promoter mutations were frequent in phyllodes tumors (30/46, 65%), but rare in fibroadenomas (4/58, 7%).	phyllodes	82-91	telomerase reverse transcriptase	Homo sapiens	41-45
26355235-9	2015	Because TERT promoter mutations are rare among fibroadenomas, their detection may be of potential use in discriminating between phyllodes tumors and fibroadenomas.	phyllodes	128-137	telomerase reverse transcriptase	Homo sapiens	8-12
26056158-0	2015	Associations of epithelial c-kit expression in phyllodes tumours of the breast.	phyllodes	47-56	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	27-32
26676988-0	2016	Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.	phyllodes	48-57	insulin like growth factor 2	Homo sapiens	22-26
26625196-10	2016	Overexpression of molecular biomarkers of increased angiogenesis, EGFR and immune checkpoints provides novel targeted therapy options in malignant phyllodes tumors of the breast.	phyllodes	147-156	epidermal growth factor receptor	Homo sapiens	66-70
26773878-10	2016	This is the first case of phyllodes tumor rapidly enlarging during anti-HER2 chemotherapy for locally advanced HER2-positive breast cancer.	phyllodes	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	72-76
26773878-10	2016	This is the first case of phyllodes tumor rapidly enlarging during anti-HER2 chemotherapy for locally advanced HER2-positive breast cancer.	phyllodes	26-35	erb-b2 receptor tyrosine kinase 2	Homo sapiens	111-115
25855048-2	2015	The aim of this study was to define whether phyllodes tumours (PTs) would harbour MED12 somatic mutations in a way akin to FAs.	phyllodes	44-53	mediator complex subunit 12	Homo sapiens	82-87
26437033-5	2015	Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.	phyllodes	8-17	filamin A	Homo sapiens	48-52
26437033-5	2015	Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.	phyllodes	8-17	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	54-59
26437033-5	2015	Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.	phyllodes	8-17	lysine methyltransferase 2D	Homo sapiens	64-69
26437033-5	2015	Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.	phyllodes	100-109	filamin A	Homo sapiens	48-52
26437033-5	2015	Second, phyllodes tumors exhibited mutations in FLNA, SETD2 and KMT2D, suggesting a role in driving phyllodes tumor development.	phyllodes	100-109	lysine methyltransferase 2D	Homo sapiens	64-69
26018969-9	2015	CONCLUSIONS: Similar to fibroadenomas, phyllodes tumours show a high frequency of MED12 mutations, affirming the close biological relationship between these fibroepithelial neoplasms.	phyllodes	39-48	mediator complex subunit 12	Homo sapiens	82-87
25795733-9	2015	LamC2 and kalinin B1 each showed positive stromal cell expression in two of 20 (10%) phyllodes tumours.	phyllodes	85-94	laminin subunit gamma 2	Homo sapiens	0-5
25865354-0	2015	MED12 exon 2 mutations in phyllodes tumors of the breast.	phyllodes	26-35	mediator complex subunit 12	Homo sapiens	0-5
25865354-3	2015	Here, we examined the MED12 mutation in phyllodes tumors, another biphasic tumor with epithelial and stromal components related to breast fibroadenomas.	phyllodes	40-49	mediator complex subunit 12	Homo sapiens	22-27
25931199-9	2015	In conclusion, we confirm the frequent occurrence of MED12 mutations in fibroadenomas, provide evidence that most intracanalicular fibroadenomas closely resembling benign phyllodes as well as benign phyllodes tumors harbor MED12 mutations, and conclude that MED12 mutations in malignant phyllodes tumors appear to be relatively rare.	phyllodes	171-180	mediator complex subunit 12	Homo sapiens	53-58
25216225-3	2015	Reports of CD117 expression in phyllodes tumors have been controversial.	phyllodes	31-40	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	11-16
25839987-0	2015	Frequent MED12 mutations in phyllodes tumours of the breast.	phyllodes	28-37	mediator complex subunit 12	Homo sapiens	9-14
25839987-9	2015	CONCLUSIONS: MED12 mutations were frequent among the phyllodes tumours of the breast, regardless of the tumour grade.	phyllodes	53-62	mediator complex subunit 12	Homo sapiens	13-18
25593300-0	2015	Next-Gen Sequencing Exposes Frequent MED12 Mutations and Actionable Therapeutic Targets in Phyllodes Tumors.	phyllodes	91-100	mediator complex subunit 12	Homo sapiens	37-42
24807638-1	2014	The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors.	phyllodes	118-127	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	87-90
25677742-0	2015	Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.	phyllodes	89-98	twist family bHLH transcription factor 1	Homo sapiens	70-75
25677742-0	2015	Prognostic significance of epithelial-mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast.	phyllodes	89-98	forkhead box C2	Homo sapiens	80-85
25046342-0	2014	A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies.	phyllodes	22-31	tumor protein p63	Homo sapiens	47-50
25046342-0	2014	A subset of malignant phyllodes tumors express p63 and p40: a diagnostic pitfall in breast core needle biopsies.	phyllodes	22-31	tumor protein p63	Homo sapiens	55-58
25046342-8	2014	CD34 labeled 57% malignant phyllodes tumors and no sarcomatoid carcinomas.	phyllodes	27-36	CD34 molecule	Homo sapiens	0-4
25046342-10	2014	In the differential diagnosis of malignant phyllodes, p40 is a more specific but less sensitive marker of sarcomatoid carcinoma than p63.	phyllodes	43-52	tumor protein p63	Homo sapiens	54-57
24807638-1	2014	The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors.	phyllodes	118-127	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	94-98
24807638-1	2014	The purpose of this study is to investigate the expression of succinate dehydrogenase (SDH)A, SDHB, and HIF-1alpha in phyllodes tumors and the association with clinic-pathologic factors.	phyllodes	118-127	hypoxia inducible factor 1 subunit alpha	Homo sapiens	104-114
24807638-9	2014	In conclusion, Tumor grade is positively correlated with SDHA and SDHB expression in the tumor stroma in phyllodes tumors of the breast.	phyllodes	105-114	succinate dehydrogenase complex flavoprotein subunit A	Homo sapiens	57-61
24807638-9	2014	In conclusion, Tumor grade is positively correlated with SDHA and SDHB expression in the tumor stroma in phyllodes tumors of the breast.	phyllodes	105-114	succinate dehydrogenase complex iron sulfur subunit B	Homo sapiens	66-70
24438019-3	2014	We aimed to investigate the expression and prognostic importance of Six1 and Pax3 homeoproteins in phyllodes tumours - a group of uncommon biphasic tumours comprising both epithelial and stromal components.	phyllodes	99-108	SIX homeobox 1	Homo sapiens	68-72
24961352-0	2014	Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors.	phyllodes	0-9	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	Homo sapiens	47-58
24961352-0	2014	Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors.	phyllodes	89-98	AXL receptor tyrosine kinase	Homo sapiens	39-42
24961352-0	2014	Phyllodes tumor of the breast: role of Axl and ST6GalNAcII in the development of mammary phyllodes tumors.	phyllodes	89-98	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	Homo sapiens	47-58
24961352-3	2014	The purpose of this study was to evaluate the implications of Axl and ST6GalNAcII in phyllodes tumors.	phyllodes	85-94	AXL receptor tyrosine kinase	Homo sapiens	62-65
24961352-3	2014	The purpose of this study was to evaluate the implications of Axl and ST6GalNAcII in phyllodes tumors.	phyllodes	85-94	ST6 N-acetylgalactosaminide alpha-2,6-sialyltransferase 2	Homo sapiens	70-81
24980553-5	2014	Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors.	phyllodes	99-108	microRNA 21	Homo sapiens	23-29
24980553-5	2014	Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors.	phyllodes	137-146	microRNA 21	Homo sapiens	23-29
24492332-1	2014	Adequate management of phyllodes tumors of the breast (PTB) remains a challenge because of the difficulty in correctly establishing preoperative diagnosis.	phyllodes	23-32	polypyrimidine tract binding protein 1	Homo sapiens	55-58
24438019-3	2014	We aimed to investigate the expression and prognostic importance of Six1 and Pax3 homeoproteins in phyllodes tumours - a group of uncommon biphasic tumours comprising both epithelial and stromal components.	phyllodes	99-108	paired box 3	Homo sapiens	77-81
23916291-0	2013	A subset of malignant phyllodes tumors harbors alterations in the Rb/p16 pathway.	phyllodes	22-31	cyclin dependent kinase inhibitor 2A	Homo sapiens	69-72
23916291-2	2013	Here, we systematically study p16 and Rb expression in 34 phyllodes tumors in relation to proliferation.	phyllodes	58-67	cyclin dependent kinase inhibitor 2A	Homo sapiens	30-33
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	69-72
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126
23916291-8	2013	Twenty-nine percent (4/14) malignant phyllodes showed diffuse strong p16 labeling with Rb loss in malignant cells (diffuse p16+/Rb-), whereas 21% (3/14) malignant phyllodes showed the reverse pattern of p16 loss with diffuse strong Rb (p16-/diffuse Rb+).	phyllodes	37-46	cyclin dependent kinase inhibitor 2A	Homo sapiens	123-126
23916291-13	2013	Ki-67 was highest in malignant phyllodes with diffuse p16+/Rb- labeling.	phyllodes	31-40	cyclin dependent kinase inhibitor 2A	Homo sapiens	54-57
23916291-14	2013	In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation.	phyllodes	26-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	59-62
23916291-14	2013	In summary, 50% malignant phyllodes display evidence of Rb/p16 pathway alterations, likely reflecting p16 or Rb inactivation.	phyllodes	26-35	cyclin dependent kinase inhibitor 2A	Homo sapiens	102-105
23895135-18	2013	CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor.	phyllodes	109-118	NRAS proto-oncogene, GTPase	Homo sapiens	47-51
23772632-4	2013	CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant.	phyllodes	112-121	catenin beta 1	Homo sapiens	15-27
23772632-4	2013	CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant.	phyllodes	168-177	CD34 molecule	Homo sapiens	0-4
23772632-4	2013	CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant.	phyllodes	112-121	CD34 molecule	Homo sapiens	0-4
23772632-4	2013	CD34, VEGF and beta-catenin in stromal cells were expressed, respectively, in: 38.3%, 29.2% and 27.5% of benign phyllodes tumours; 33.3%, 58.3% and 54.2% of borderline phyllodes tumours; and 5.9%, 64.7% and 76.5% of malignant phyllodes tumours; these associations with histological grade were statistically significant.	phyllodes	112-121	vascular endothelial growth factor A	Homo sapiens	6-10
23794094-0	2013	A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.	phyllodes	53-62	tumor protein p53	Homo sapiens	2-6
23794094-1	2013	A few studies have reported phyllodes tumors (PT) of the breast with germline TP53 mutations.	phyllodes	28-37	tumor protein p53	Homo sapiens	78-82
23895135-18	2013	CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor.	phyllodes	109-118	AKT serine/threonine kinase 1	Homo sapiens	97-100
23895135-18	2013	CONCLUSIONS: We describe for the first time an NRAS mutation with concomitant activation of PI3K/Akt/mTOR in phyllodes tumor.	phyllodes	109-118	mechanistic target of rapamycin kinase	Homo sapiens	101-105
20497245-0	2010	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.	phyllodes	93-102	cyclin dependent kinase inhibitor 2A	Homo sapiens	0-3
23150175-0	2013	Expression of TWIST1, Snail, Slug, and NF-kappaB and methylation of the TWIST1 promoter in mammary phyllodes tumor.	phyllodes	99-108	twist family bHLH transcription factor 1	Homo sapiens	72-78
23291960-0	2013	Ubiquitin carboxy-terminal hydrolase L1 may be involved in the development of mammary phyllodes tumors.	phyllodes	86-95	ubiquitin C-terminal hydrolase L1	Homo sapiens	0-39
22571452-0	2012	Involvement of alpha- and beta-catenins and E-cadherin in the development of mammary phyllodes tumours.	phyllodes	85-94	cadherin 1	Homo sapiens	15-54
22816226-24	2012	Stromal cells in phyllodes tumors are more PCNA positive than in fibroadenomas, also Ki-67 and androgen receptors are more positive in phyllodes tumors.	phyllodes	17-26	proliferating cell nuclear antigen	Homo sapiens	43-47
20563638-13	2010	Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001).	phyllodes	77-86	Ras association domain family member 1	Homo sapiens	9-16
20563638-13	2010	Elevated RASSF1A and/or TWIST1 methylation was significantly associated with phyllodes tumours compared with fibroadenomas (P = 0.02), TWIST1 methylation correlated with increasing malignancy in phyllodes tumours (P < 0.001).	phyllodes	77-86	twist family bHLH transcription factor 1	Homo sapiens	24-30
22820000-0	2012	E-cadherin expression in the epithelial components of mammary phyllodes tumors.	phyllodes	62-71	cadherin 1	Homo sapiens	0-10
22006372-4	2012	The purpose of this study was to evaluate the usefulness of immunohistochemical staining of stromal CD10 in predicting the likelihood of metastasis in phyllodes tumors.	phyllodes	151-160	membrane metalloendopeptidase	Homo sapiens	100-104
22006372-5	2012	METHODS: The expression of CD10 was studied in 43 phyllodes tumors (16 benign, 10 borderline, and 17 malignant) using immunohistochemistry to evaluate whether differences in expression correlated with the presence of, and or, development of distant metastasis.	phyllodes	50-59	membrane metalloendopeptidase	Homo sapiens	27-31
22006372-8	2012	CONCLUSIONS: The expression of CD10 can be used to predict the occurrence of distant metastasis in phyllodes tumors of the breast.	phyllodes	99-108	membrane metalloendopeptidase	Homo sapiens	31-35
21030860-5	2011	p53 and phospho-Histone3 (mitotic marker) showed increased staining in higher grade phyllodes tumors.	phyllodes	84-93	tumor protein p53	Homo sapiens	0-3
20693983-0	2010	beta-catenin/Wnt signalling pathway in fibromatosis, metaplastic carcinomas and phyllodes tumours of the breast.	phyllodes	80-89	catenin beta 1	Homo sapiens	0-12
20497245-0	2010	p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours.	phyllodes	93-102	RB transcriptional corepressor 1	Homo sapiens	8-11
15725803-9	2005	The stromal component of all phyllodes tumors was positive for vimentin, whereas all other investigated markers were absent except for focal p63 and CD10 expression in 1 case each.	phyllodes	29-38	vimentin	Homo sapiens	63-71
19170049-2	2009	More recently, epithelial-stromal (ES) tumors resembling phyllodes tumors have been described in the seminal vesicles of TRAMP mice.	phyllodes	57-66	tumor necrosis factor receptor superfamily, member 25	Mus musculus	121-126
16554735-0	2006	Estrogen receptor-beta is expressed in stromal cells of fibroadenoma and phyllodes tumors of the breast.	phyllodes	73-82	estrogen receptor 2	Homo sapiens	0-22
16554735-6	2006	The highest percentage of ER-beta was observed in fibroadenomas with cellular stroma and in phyllodes tumors.	phyllodes	92-101	estrogen receptor 2	Homo sapiens	26-33
16554735-9	2006	In contrast, in phyllodes tumors, ER-beta expression was higher in older patients.	phyllodes	16-25	estrogen receptor 2	Homo sapiens	34-41
16889904-0	2006	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.	phyllodes	99-108	tumor protein p53	Homo sapiens	15-18
16889904-0	2006	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.	phyllodes	99-108	MIB E3 ubiquitin protein ligase 1	Homo sapiens	23-28
16889904-9	2006	Positive staining for p53 was seen in 10 phyllodes tumors (24%), and the median MIB-1 index was 10%.	phyllodes	41-50	tumor protein p53	Homo sapiens	22-25
18500266-1	2008	The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations.	phyllodes	78-87	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	18-23
18500266-1	2008	The expression of c-kit, a protooncogene tyrosine kinase receptor (CD117), in phyllodes tumors of the breast has been the subject of recent investigations.	phyllodes	78-87	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	67-72
17158636-0	2007	Endothelin-1 expression correlates with atypical histological features in mammary phyllodes tumours.	phyllodes	82-91	endothelin 1	Homo sapiens	0-12
18032821-0	2007	Egfr amplification specific gene expression in phyllodes tumours of the breast.	phyllodes	47-56	epidermal growth factor receptor	Homo sapiens	0-4
18032821-2	2007	METHODS: In order to gain further insights into regulation mechanisms associated with egfr amplifications and EGFR expression in phyllodes tumours, we performed global gene expression analysis (Affymetrix A133.2) on a series of 10 phyllodes tumours, of these three with and seven without amplifications of an important regulatory repeat in intron 1 of egfr (CA-SSR I).	phyllodes	129-138	epidermal growth factor receptor	Homo sapiens	110-114
18032821-4	2007	RESULTS: We were able to show that the presence of egfr CA-SSR I amplifications in phyllodes tumours was associated with 230 differentially expressed genes.	phyllodes	83-92	epidermal growth factor receptor	Homo sapiens	51-55
16554735-10	2006	In conclusion, (i) only ER-beta is detected in the stroma of fibroadenomas and phyllodes tumors; (ii) its expression correlates with the expression of smooth muscle markers and suggests a role of ER-beta in myofibroblastic differentiation of stromal cells.	phyllodes	79-88	estrogen receptor 2	Homo sapiens	24-31
15917410-0	2005	Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.	phyllodes	84-93	nitric oxide synthase 2	Homo sapiens	8-29
15452163-6	2004	CONCLUSION: c-KIT expression is a frequent finding in phyllodes tumours, particularly in malignant cases; however, no activating mutations similar to those described for gastrointestinal stromal tumours were found.	phyllodes	54-63	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	12-17
15677540-0	2005	Stromal CD10 expression in mammary fibroadenomas and phyllodes tumours.	phyllodes	53-62	membrane metalloendopeptidase	Homo sapiens	8-12
15677540-5	2005	Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours.	phyllodes	83-92	membrane metalloendopeptidase	Homo sapiens	8-12
15677540-5	2005	Stromal CD10 expression was positive in one of 33 fibroadenomas, six of 102 benign phyllodes tumours, 16 of 51 borderline malignant phyllodes tumours, and 14 of 28 frankly malignant phyllodes tumours.	phyllodes	132-141	membrane metalloendopeptidase	Homo sapiens	8-12
16168127-9	2005	Interestingly, concerted CAIX and HIF-1alpha expression was frequently found in morphologically normal epithelium of phyllodes tumors.	phyllodes	117-126	carbonic anhydrase 9	Homo sapiens	25-29
16168127-9	2005	Interestingly, concerted CAIX and HIF-1alpha expression was frequently found in morphologically normal epithelium of phyllodes tumors.	phyllodes	117-126	hypoxia inducible factor 1 subunit alpha	Homo sapiens	34-44
16168127-12	2005	High expression of VEGF was regularly found in both tumors, with only a positive relation between stromal VEGF and grade in phyllodes tumors (P = 0.016).	phyllodes	124-133	vascular endothelial growth factor A	Homo sapiens	19-23
16168127-13	2005	Stromal HIF-1alpha overexpression in phyllodes tumors was predictive of disease-free survival (P = 0.032).	phyllodes	37-46	hypoxia inducible factor 1 subunit alpha	Homo sapiens	8-18
16168127-16	2005	In contrast, coexpression of HIF-1alpha and CAIX in the epithelium in phyllodes tumors points to epithelial hypoxia, most probably caused by relatively distant blood vessels.	phyllodes	70-79	hypoxia inducible factor 1 subunit alpha	Homo sapiens	29-39
16168127-16	2005	In contrast, coexpression of HIF-1alpha and CAIX in the epithelium in phyllodes tumors points to epithelial hypoxia, most probably caused by relatively distant blood vessels.	phyllodes	70-79	carbonic anhydrase 9	Homo sapiens	44-48
15522319-0	2004	Perioperative diagnosis of cystosarcoma phyllodes of the breast may be enhanced by MIB-1 index.	phyllodes	40-49	MIB E3 ubiquitin protein ligase 1	Homo sapiens	83-88
16168127-2	2005	We studied the expression and prognostic relevance of HIF-1alpha and its downstream targets in phyllodes tumors and fibroadenomas of the breast.	phyllodes	95-104	hypoxia inducible factor 1 subunit alpha	Homo sapiens	54-64
15343505-0	2004	Stromal expression of vascular endothelial growth factor correlates with tumor grade and microvessel density in mammary phyllodes tumors: a multicenter study of 185 cases.	phyllodes	120-129	vascular endothelial growth factor A	Homo sapiens	22-56
15343505-7	2004	Assessment of stromal VEGF may be useful as an adjunctive diagnostic criterion in the histologic assessment of malignancy in phyllodes tumors.	phyllodes	125-134	vascular endothelial growth factor A	Homo sapiens	22-26
15044924-0	2004	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors.	phyllodes	56-65	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	10-15
15044924-0	2004	Increased c-kit (CD117) expression in malignant mammary phyllodes tumors.	phyllodes	56-65	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	17-22
15044924-6	2004	The overall positive rate for c-kit was 29% (52/179) and 17% (17/101), 24% (12/50) and 46% (13/28), respectively, for benign, borderline malignant and frank malignant phyllodes and the differences between all categories were significant (chi2=13.844, P=0.001).	phyllodes	167-176	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	30-35
11070114-4	2000	There was neoplastic stromal cell positivity for PDGFRbeta in almost 50% of phyllodes tumors and for PDGF in 24%.	phyllodes	76-85	platelet derived growth factor receptor beta	Homo sapiens	49-58
15638374-5	2004	Our results show that Ki-67 and PCNA may be useful in the evaluation of stromal proliferation in phyllodes tumours (PT), which play an integral part in the progression from PTLGM through PTBM to PTHGM.	phyllodes	97-106	proliferating cell nuclear antigen	Homo sapiens	32-36
14559983-6	2003	P53 protein expression showed a positive correlation with microvessel density, suggesting possible overlap in the underlying mechanism of these two factors in the pathogenesis of phyllodes tumors.	phyllodes	179-188	tumor protein p53	Homo sapiens	0-3
14559983-8	2003	We conclude that microvessel density and p53 are useful as independent criteria in evaluating malignancy in phyllodes tumors.	phyllodes	108-117	tumor protein p53	Homo sapiens	41-44
11135048-0	2001	Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast.	phyllodes	32-41	CD34 molecule	Homo sapiens	14-18
11135048-0	2001	Expression of CD34 and bcl-2 in phyllodes tumours, fibroadenomas and spindle cell lesions of the breast.	phyllodes	32-41	BCL2 apoptosis regulator	Homo sapiens	23-28
12898599-1	2003	The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours.	phyllodes	74-83	insulin like growth factor 1	Homo sapiens	54-59
12898599-1	2003	The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours.	phyllodes	74-83	insulin like growth factor 2	Homo sapiens	64-70
12898599-1	2003	The aim of this study was to assess the expression of IGF-I and IGF-II in phyllodes tumours and fibroadenomas and to see if there is any correlation between nuclear beta-catenin expression and IGF-I and IGF-II expression in these tumours.	phyllodes	74-83	insulin like growth factor 1	Homo sapiens	64-69
12898599-2	2003	In a previous study, it has been shown that Wnt signalling is important in the pathogenesis of phyllodes tumours of the breast.	phyllodes	95-104	Wnt family member 2	Homo sapiens	44-47
12898599-7	2003	In situ hybridization was used to assess IGF-I and IGF-II expression in 23 phyllodes tumours and 16 fibroadenomas.	phyllodes	75-84	insulin like growth factor 2	Homo sapiens	51-57
12118111-0	2002	Increased p53 protein expression in malignant mammary phyllodes tumors.	phyllodes	54-63	tumor protein p53	Homo sapiens	10-13
11815995-0	2002	Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.	phyllodes	48-57	tumor protein p53	Homo sapiens	20-23
11815995-0	2002	Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.	phyllodes	48-57	erb-b2 receptor tyrosine kinase 2	Homo sapiens	36-44
11070114-6	2000	Co-positivity for stromal PDGF and PDGFRbeta was found in 15% of phyllodes tumors, and for epithelial PDGF and stromal PDGFRbeta in 43%.	phyllodes	65-74	platelet derived growth factor receptor beta	Homo sapiens	35-44
2454275-3	1987	Vimentin and desmin were detected in the sarcomatous portion of carcinosarcoma, focally in the stromal component of phyllodes tumors and not always in the stromal sarcomas.	phyllodes	116-125	vimentin	Homo sapiens	0-8
10547570-11	1999	It is concluded that p53 gene status and an accumulation of BAX, both involved in the same apoptosis-controlling pathway, may be of prognostic relevance in phyllodes tumours.	phyllodes	156-165	tumor protein p53	Homo sapiens	21-24
10547570-11	1999	It is concluded that p53 gene status and an accumulation of BAX, both involved in the same apoptosis-controlling pathway, may be of prognostic relevance in phyllodes tumours.	phyllodes	156-165	BCL2 associated X, apoptosis regulator	Homo sapiens	60-63
7687354-2	1993	In this study, C-erbB-2 expression was studied immunohistochemically on frozen sections in 63 infiltrating carcinomas, 3 phyllodes tumours, 15 fibroadenomas and 16 cases of fibrocystic disease.	phyllodes	121-130	erb-b2 receptor tyrosine kinase 2	Homo sapiens	15-23
33782741-5	2021	KMT2D and SETD2 mutations were present in both the conventional phyllodes tumour and endometriosis-like areas and are also described in endometriosis raising interesting questions about these lesions.	phyllodes	64-73	lysine methyltransferase 2D	Homo sapiens	0-5
33782741-5	2021	KMT2D and SETD2 mutations were present in both the conventional phyllodes tumour and endometriosis-like areas and are also described in endometriosis raising interesting questions about these lesions.	phyllodes	64-73	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	10-15
9584322-5	1998	Our results also indicate a good correlation between the conventional grading of phyllodes tumours based on histological criteria and MIB1 indices.	phyllodes	81-90	MIB E3 ubiquitin protein ligase 1	Homo sapiens	134-138
34597441-5	2021	MED12 mutation was identified in 19 primary tumors (12 phyllodes tumors and 7 fibroadenomas) and 17 recurrences (14 phyllodes tumors and three fibroadenomas).	phyllodes	55-64	mediator complex subunit 12	Homo sapiens	0-5
34597441-5	2021	MED12 mutation was identified in 19 primary tumors (12 phyllodes tumors and 7 fibroadenomas) and 17 recurrences (14 phyllodes tumors and three fibroadenomas).	phyllodes	116-125	mediator complex subunit 12	Homo sapiens	0-5
34597441-8	2021	TERT promoter mutation was identified in 13 primary phyllodes tumors (13/19) and 15 recurrent phyllodes tumors (15/19).	phyllodes	52-61	telomerase reverse transcriptase	Homo sapiens	0-4
34597441-11	2021	Our findings suggest that recurrent phyllodes tumors may be "true recurrence," and TERT mutant "benign fibroepithelial tumors" should be treated as phyllodes tumors.	phyllodes	148-157	telomerase reverse transcriptase	Homo sapiens	83-87
2704424-3	1989	It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas.	phyllodes	62-71	cathepsin B	Homo sapiens	111-122
2704424-3	1989	It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas.	phyllodes	62-71	cathepsin B	Homo sapiens	173-184
2704424-3	1989	It was found that primary breast carcinomas and cystosarcomas phyllodes contain significantly higher levels of cathepsin B activity than mammary dysplasias; the activity of cathepsin B in cystosarcomas phyllodes was comparable with that in breast carcinomas.	phyllodes	202-211	cathepsin B	Homo sapiens	173-184
2454275-3	1987	Vimentin and desmin were detected in the sarcomatous portion of carcinosarcoma, focally in the stromal component of phyllodes tumors and not always in the stromal sarcomas.	phyllodes	116-125	desmin	Homo sapiens	13-19
33863915-2	2021	TERT promoter hotspot mutations and gene amplification are rare in common forms of breast cancer, but present in a subset of phyllodes tumors.	phyllodes	125-134	telomerase reverse transcriptase	Homo sapiens	0-4
193460-0	1977	Progesterone receptor in cystosarcoma phyllodes.	phyllodes	38-47	progesterone receptor	Homo sapiens	0-21
33844099-0	2021	SETD2 alterations and histone H3K36 trimethylation in phyllodes tumor of breast.	phyllodes	54-63	SET domain containing 2, histone lysine methyltransferase	Homo sapiens	0-5
32857809-0	2020	Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.	phyllodes	45-54	epithelial membrane protein 1	Homo sapiens	14-18
33026185-7	2021	A marked difference in NGF expression was detected in phyllodes tumors compared to fibroadenomas.	phyllodes	54-63	nerve growth factor	Homo sapiens	23-26
33026185-8	2021	The maximum NGF expression was observed in phyllodes tissue followed by cancer tissue, and the least expression in fibroadenomas (3-5 times less than in phyllodes; comparable with normal breast tissue).	phyllodes	43-52	nerve growth factor	Homo sapiens	12-15
33026185-10	2021	This study reports abundant NGF secretion by breast phyllodes, raising the possibility of its potential role in tumor pathogenesis and progression that can be exploited therapeutically.	phyllodes	52-61	nerve growth factor	Homo sapiens	28-31
33026185-11	2021	Additionally, NGF may be used as a distinct biomarker of phyllodes tumors, for differentiating them from fibroadenomas during histopathology.	phyllodes	57-66	nerve growth factor	Homo sapiens	14-17
33245988-7	2021	Stromal cells expressed LEF-1 in 100% (16/16 of core TMA) of malignant phyllodes, compared to 73% (16/22) borderline and 27% (13/48) benign tumors.	phyllodes	71-80	lymphoid enhancer binding factor 1	Homo sapiens	24-29
33447858-11	2021	CONCLUSIONS: We encountered a rare case of G-CSF-producing malignant phyllodes tumor of the breast.	phyllodes	69-78	colony stimulating factor 3	Homo sapiens	43-48
32986365-0	2020	Ki67 and P53 Expression in Relation to Clinicopathological Features in Phyllodes Tumour of the Breast.	phyllodes	71-80	tumor protein p53	Homo sapiens	9-12
32857809-0	2020	Expression of EMP1, EMP2, and EMP3 in breast phyllodes tumors.	phyllodes	45-54	epithelial membrane protein 3	Homo sapiens	30-34
32116328-4	2020	By contrast, canalicular carcinoma (Grades I and IIB) and phyllodes tumors had very low expression levels of BIK.	phyllodes	58-67	BCL2 interacting killer	Homo sapiens	109-112
29608014-0	2018	Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.	phyllodes	68-77	integrin linked kinase	Homo sapiens	27-49
30486739-3	2018	This work was undertaken to evaluate the expression of B7-H3 and B7-H4 in phyllodes tumors and assess the association with the grade and clinical behavior of phyllodes tumors.	phyllodes	74-83	CD276 antigen	Mus musculus	55-60
30486739-7	2018	B7-H3 messenger RNA and protein appeared to be concentrated mainly in the stromal compartment of phyllodes tumors.	phyllodes	97-106	CD276 antigen	Mus musculus	0-5
30486739-9	2018	Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively.	phyllodes	104-113	CD276 antigen	Mus musculus	8-13
30486739-9	2018	Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively.	phyllodes	165-174	CD276 antigen	Mus musculus	8-13
30486739-9	2018	Stromal B7-H3 messenger RNA and protein expression were noted in 10 (16.7%) and 31 (51.7%) of 60 benign phyllodes tumors, 12 (46.1%) and 20 (76.9%) of 26 borderline phyllodes tumors, and 10 (66.7%) and 13 (86.7%) of 15 malignant phyllodes tumors, respectively.	phyllodes	165-174	CD276 antigen	Mus musculus	8-13
30486739-10	2018	Stromal B7-H3 messenger RNA and protein expression increased as phyllodes tumors progressed from benign to borderline and finally to the malignant grade (Pearson"s R = 0.411, p < 0.001 and Pearson"s R = 0.293, p = 0.003, respectively).	phyllodes	64-73	CD276 antigen	Mus musculus	8-13
30486739-13	2018	These results suggest that B7-H3 is involved in the progression of phyllodes tumors and may contribute to their immune surveillance.	phyllodes	67-76	CD276 antigen	Mus musculus	27-32
31192133-1	2019	Purpose: To determine the potential of mammography (MG) and mammographic texture analysis in differentiation between Grade 1 (G1) and Grade 2/ Grade 3 (G2/G3) phyllodes tumors (PTs) of breast.	phyllodes	159-168	crystallin gamma E, pseudogene	Homo sapiens	117-157
30383904-0	2019	Expression of biomarkers in the AKT pathway correlates with malignancy and recurrence in phyllodes tumours of the breast.	phyllodes	89-98	AKT serine/threonine kinase 1	Homo sapiens	32-35
29608014-0	2018	Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.	phyllodes	68-77	integrin linked kinase	Homo sapiens	51-54
29608014-0	2018	Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.	phyllodes	68-77	zinc finger E-box binding homeobox 1	Homo sapiens	60-64
29608014-4	2018	In this study, we aimed to investigate ILK and EMT markers expression in phyllodes breast tumors in relation to tumor grade.	phyllodes	73-82	integrin linked kinase	Homo sapiens	39-42
28968268-7	2018	Focal expression (5% of the tumor cells) of cytokeratin cocktail and p63 was identified in the stroma of 2 of 10 malignant phyllodes tumors in a scattered/patchy pattern.	phyllodes	123-132	tumor protein p63	Homo sapiens	69-72
29043292-2	2017	TERT promoter hotspot mutations have been documented in phyllodes tumors, and found to be more frequent in borderline and malignant lesions.	phyllodes	56-65	telomerase reverse transcriptase	Homo sapiens	0-4
29315289-1	2018	BACKGROUND: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes tumours (PTs).	phyllodes	105-114	mediator complex subunit 12	Homo sapiens	12-17
29315289-1	2018	BACKGROUND: MED12 and TERT promoter mutations have been shown to be the most common somatic mutations in phyllodes tumours (PTs).	phyllodes	105-114	telomerase reverse transcriptase	Homo sapiens	22-26
28380418-8	2017	These findings show that expression of EMT markers, the mode of surgical management, and a history of recent tumor growth had prognostic potential for patients with phyllodes tumors of the breast.	phyllodes	165-174	IL2 inducible T cell kinase	Homo sapiens	39-42
28029685-11	2017	CD34 (a marker often positive in phyllodes tumours) is consistently negative in MBC.	phyllodes	33-42	CD34 molecule	Homo sapiens	0-4